Research Topics
| S A GrossmanSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Management of pineal region tumorsJaishri O Blakeley
Brain Cancer Program, Johns Hopkins University, Cancer Research Building 2, 1550 Orleans Street, Suite 1M16, Baltimore, MD 21231, USA
Curr Treat Options Oncol 7:505-16. 2006..Patients with tectal gliomas may undergo excision with or without postoperative radiation; however, they also may be observed with vigilant follow-up alone...
Phase I study of terameprocol in patients with recurrent high-grade gliomaStuart A Grossman
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Neuro Oncol 14:511-7. 2012..The long-term stability noted in some patients and the lack of associated myelosuppression suggest that terameprocol could be safely combined with radiation and temozolomide in newly diagnosed high-grade gliomas...- Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomasS A Grossman
Johns Hopkins Oncology Center, Baltimore 21231, MD, USA
J Clin Oncol 19:3260-6. 2001..To determine the toxicity, efficacy, and pharmacology of suramin in patients with recurrent or progressive recurrent high-grade gliomas... - Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomasStuart A Grossman
The New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD 21231, USA
Neuro Oncol 7:32-40. 2005..No clinical benefit was seen. The rapid deterioration seen in these patients could result from tumor growth or an effect of aprinocarsen on bloodbrain barrier integrity... - The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochlorideStuart A Grossman
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Massachusetts General Hospital, Boston, USA
Clin Cancer Res 12:5174-81. 2006..This study was conducted to determine if the maximum tolerated dose and pharmacokinetics of PCB are affected by the concurrent use of enzyme-inducing antiseizure drugs (EIASD)... - Cancer pain management in the 21st centuryStuart A Grossman
The Cancer Pain Service, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Oncology (Williston Park) 20:1333-9; discussion 1340-2, 1347-8, 1351. 2006..An effective strategy to make alleviating pain a major health-care priority remains the primary challenge to effectively palliating patients with cancer pain... - Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative OncolStuart A Grossman
1650 Orleans St, Room G93, The Sydney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
J Clin Oncol 21:1485-91. 2003..The control arm consisted of radiation with standard adjuvant BiCNU... - Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastomaStuart A Grossman
NABTT CNS Consortium, 1550 Orleans Street, Baltimore, MD 21231, USA
Neuro Oncol 10:190-8. 2008..Celecoxib administered during and after radiation is well tolerated. The potential difference in survival between the +EIASD and -EIASD groups deserves further evaluation... - Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomasStuart A Grossman
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 1000, USA
Neuro Oncol 10:608-16. 2008..The total body clearance of karenitecin is significantly enhanced by the concurrent administration of EIASDs. This schedule of karenitecin, a novel lipophilic camptothecin analogue, has little activity in recurrent MG... - Current management of glioblastoma multiformeStuart A Grossman
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Semin Oncol 31:635-44. 2004.... - Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trialStuart A Grossman
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans St, Baltimore, MD 21231, USA
J Clin Oncol 27:4155-61. 2009..Talampanel is a well-tolerated, oral alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor blocker that could be beneficial in this disease... - Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomideStuart A Grossman
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, Maryland 21231, USA
Clin Cancer Res 17:5473-80. 2011..As each of these is immunosuppressive, we conducted a prospective, multicenter study to follow CD4 counts over time and determine whether low CD4 counts were associated with adverse outcomes... - Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United StatesStuart A Grossman
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA
Clin Cancer Res 16:2443-9. 2010..Results of these phase II studies are typically compared with the phase III European Organization for Research and Treatment of Cancer (EORTC) survival data that resulted in RT + TMZ becoming standard therapy... - Leptomeningeal carcinomatosisS A Grossman
The Johns Hopkins Oncology Center, 600 North Wolfe Street, Baltimore, MD, 21287, USA
Cancer Treat Rev 25:103-19. 1999..Further information on the mechanisms of neurotoxicity from antineoplastic agents is critical to providing better outcomes for this increasing common complication of cancer... - Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytomaS A Grossman
The Johns Hopkins Medical Institutions, Baltimore, MD, USA
J Clin Oncol 15:2596-603. 1997..To evaluate the activity and toxicity of carmustine (BCNU) and cisplatin administered as a 72-hour continuous intravenous infusion before radiation in adults with newly diagnosed high-grade astrocytomas... - Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiformeL Kleinberg
Johns Hopkins Oncology Center, Baltimore, MD, USA
J Clin Oncol 17:2593-603. 1999..RSR13, a synthetic allosteric modifier of hemoglobin (HgB), is a novel radioenhancing agent that noncovalently binds to HgB, thereby reducing oxygen binding affinity and increasing tissue oxygen release to hypoxic tissues... - Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor TherapyS A Grossman
The Central Operations Office, The NABTT CNS Consortium, The Johns Hopkins Oncology Center, Baltimore, MD 21287, USA
Cancer Chemother Pharmacol 42:118-26. 1998..As existing chemotherapeutic agents are of limited benefit, clinical trials are underway to screen new drugs, such as 9-aminocamptothecin (9-AC), for activity in high grade astrocytomas... - The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytomaL Kleinberg
Division of Radiation Oncology, Johns Hopkins Oncology Center, Baltimore, MD, USA
Int J Radiat Oncol Biol Phys 44:535-43. 1999..To determine the effects of sequential versus concurrent administration of cranial radiotherapy and cisplatin/carmustine (BCNU) chemotherapy on survival and toxicity in newly diagnosed high-grade astrocytomas... - Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiationElizabeth R Gerstner
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Neurology 70:401-2. 2008 - Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic studySurasak Phuphanich
The New Approaches to Brain Tumor Therapy CNS Consortium, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
Neuro Oncol 7:177-82. 2005..The pharmacology of PB appears to be affected by concomitant administration of P450-inducing anticonvulsants... - Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy studyL Kleinberg
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 2410, USA
J Clin Oncol 20:3149-55. 2002..RSR13, a synthetic allosteric modifier of hemoglobin, is a radiation-enhancing agent that noncovalently binds to hemoglobin, reduces oxygen-binding affinity, and increases oxygen unloading to hypoxic tissue... 
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiformeMatthew J McGirt
Departments of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
J Neurosurg 110:583-8. 2009..The authors reviewed their initial experience utilizing combined Gliadel, TMZ, and radiation therapy for the treatment of GBM...- Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trialJon Weingart
New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD, USA
J Clin Oncol 25:399-404. 2007.... - Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11Tracy T Batchelor
Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
Neuro Oncol 6:21-7. 2004..Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations... - Phase I and correlative biology study of cilengitide in patients with recurrent malignant gliomaL Burt Nabors
New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD 21231, USA
J Clin Oncol 25:1651-7. 2007..This multi-institutional phase I trial was designed to determine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perfusion magnetic resonance imaging (MRI) in patients with recurrent malignant glioma... - Treatment of relapsed central nervous system lymphoma with high-dose methotrexateScott R Plotkin
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Clin Cancer Res 10:5643-6. 2004..The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma... - A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomasJana Portnow
The Johns Hopkins Oncology Center, Baltimore, MD 21231-1000, USA
Neuro Oncol 4:22-5. 2002..2). These results suggest that a selective COX-2 inhibitor appears to be as effective as dexamethasone in prolonging survival in a rat brain tumor model... - Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient managementLawrence R Kleinberg
Johns Hopkins Oncology Center, Johns Hopkins University, 401 North Broadway, Baltimore, MD 21231, USA
Cancer Invest 22:1-9. 2004..Therefore, the possibility of necrosis/treatment effect should be considered for each patient with radiographic findings suspicious for local recurrence... - Herpes simplex encephalitis in a patient with recurrent pituitary adenoma receiving radiation therapyTien Peng
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA
Am J Clin Oncol 30:664-5. 2007 - Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07Tracy Batchelor
Massachusetts General Hospital, Boston, MA, USA
J Clin Oncol 21:1044-9. 2003..A multicenter, phase II study of single-agent, intravenous methotrexate in newly diagnosed non-AIDS-related primary CNS lymphoma was conducted in the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium... - Primary central nervous system lymphomasJulette F Batara
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Curr Opin Neurol 16:671-5. 2003..Further progress in this uncommon disease will depend on entering patients into carefully designed multicenter clinical trials to build upon the significant advances that have been made... - Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trialAlessandro Olivi
The New Approaches to Brain Tumor Therapy CNS Consortium, 1650 Orleans St, Room G93, The Sydney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
J Clin Oncol 21:1845-9. 2003.... - Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trialsKathryn A Carson
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
J Clin Oncol 25:2601-6. 2007..Prognostic factor analyses have proven useful in predicting outcome in patients with newly diagnosed malignant glioma. Similar analyses in patients with recurrent glioma could affect the design and conduct of clinical trials substantially... - The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomasDavid E Gerber
Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Neuro Oncol 9:47-52. 2007.... - Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis studyJaishri O Blakeley
Johns Hopkins University School of Medicine, Cancer Research Building II, 1550 Orleans Street, Suite 1M16, Baltimore, MD, 21231, USA
J Neurooncol 91:51-8. 2009..This study investigated the use of microdialysis to assess intratumoral drug distribution in patients with recurrent high grade gliomas (HGG)... - Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomasStuart A Grossman
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
Semin Oncol 30:19-22. 2003..Improving outcome in high-grade gliomas requires an emphasis on discovering novel therapies and improving the design of adjuvant trials... - Controversies in the adjuvant therapy of high-grade gliomasMatthias Holdhoff
Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Oncologist 16:351-8. 2011..be extrapolated to patients aged >70 and to patients with lower grade gliomas? and (d) How should novel therapeutic approaches be added to radiation and temozolomide in clinical trials for patients with newly diagnosed glioblastoma?.. - Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literatureMary Y Armanios
Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
Neuro Oncol 6:259-63. 2004..The patient died 2 weeks after the diagnosis was established. The patient receiving the donor liver also developed GBM. We present a case study, review of the literature, and suggested interventions to minimize the risk of transmission... - An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trialStephen B Tatter
Department of Neurosurgery, Wake Forest University, Winston Salem, North Carolina, USA
J Neurosurg 99:297-303. 2003..In this study the authors evaluated the safety and performance of the GliaSite Radiation Therapy System (RTS) in patients with recurrent malignant brain tumors who were undergoing tumor resection... - Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiformeMatthias Holdhoff
Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Cancer Research Building II, Suite 1 M 16 1550 Orleans Street, Baltimore, MD, 21231, USA
J Neurooncol 97:241-5. 2010.... - Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium studyJohn J Laterra
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Neuro Oncol 6:15-20. 2004..However, overall survival is not significantly improved when compared with the New Approaches to Brain Tumor Therapy GBM database or other comparable patient populations... - Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomideAna De Jesus
Johns Hopkins Hospital, Baltimore, USA
J Neurooncol 94:445-8. 2009..This case highlights the potential for severe opportunistic infections in this patient population after severe immunosuppression... - Association between hyperglycemia and survival in patients with newly diagnosed glioblastomaRachel L Derr
c o The NABTT CNS Consortium, Cancer Research Building 2, Suite 1M 16, 1550 Orleans St, Baltimore, MD 21231, USA
J Clin Oncol 27:1082-6. 2009..Time-weighted mean glucose and mean glucocorticoid dose were calculated for each patient using all values collected regularly in follow-up. The primary outcome was survival... - Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumorsAnuj K Mahindra
The Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231-1000, USA
J Neurooncol 63:263-70. 2003..Since effective prophylaxis exists, it should be considered in patients with brain tumors receiving high dose steroids, high dose methotrexate or with lymphopenia... - Central nervous system cancers in first-degree relatives and spousesS A Grossman
Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Cancer Invest 17:299-308. 1999..Although this hypothesis requires further study, it is plausible given the known associations in animals and humans between high-grade astrocytomas and radiation, toxic chemicals, and viruses... - Feasibility of quantitative pain assessment in outpatient oncology practiceD J Rhodes
Johns Hopkins Hospital and St Agnes Hospital, Baltimore, MD, USA
J Clin Oncol 19:501-8. 2001..Pain score collection identified a high prevalence of pain, patient subgroups at risk for pain, and a significant proportion of patients with pain that was neither evaluated nor treated by their oncologists... - Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposiumRamsis K Benjamin
Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
Neuro Oncol 6:65-74. 2004..In doing so we provide a rationale for the use of this technology by a National Cancer Institute consortium, New Approaches to Brain Tumor Therapy, to measure levels of drugs in brain tissue as part of phase 1 trials... - Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxisDavid E Gerber
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
Cancer 109:300-5. 2007..Therefore, we conducted a retrospective review of postoperative meningioma patients receiving contemporary VTE prophylaxis and diagnostic methods to define the current incidence of and risk factors for symptomatic VTE in this population... - A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant settingE Antonio Chiocca
The NABTT CNS Consortium, Baltimore, MD 21231, USA
Mol Ther 10:958-66. 2004..In 2 patients who underwent a second resection 3 months after ONYX-015 injection, a lymphocytic and plasmacytoid cell infiltrate was observed. Injection of ONYX-015 into glioma cavities is well tolerated at doses up to 10(10) pfu... - Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literatureJohann C Brandes
Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Cancer Invest 24:283-7. 2006..Thymidine and carboxypeptidase were not available. Dialysis was unsuccessful in removing pemetrexed. Theoretical and practical approaches to management of similar cases are presented... - Epigenetic silencing of multiple genes in primary CNS lymphomaLinda C Chu
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
Int J Cancer 119:2487-91. 2006..Our study provides insight into the epigenetic alterations in PCNSL and provides potential biomarkers of disease... - Transmission of glioblastoma multiforme after bilateral lung transplantationHongbin Chen
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA
J Clin Oncol 26:3284-5. 2008 - Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphomaDavid E Gerber
The New Approaches to Brain Tumor Therapy NABTT CNS Consortium, 1550 Orleans Street, Cancer Research Building II, Suite 1M16, Baltimore, MD 21231, USA
Cancer Chemother Pharmacol 59:817-23. 2007..Because these collections are cumbersome and at times unreliable, the use of a calculated CrCl was evaluated as a potential alternative... - Tissue and tumor distribution of C-penclomedine in ratsS O'Reilly
The Johns Hopkins Oncology Center, Baltimore, Maryland 21287, USA
Clin Cancer Res 2:541-8. 1996..The finding of penclomedine in normal brain tissue indicates not only that this drug may be useful in tumors with normal blood-brain barrier function, but also that it may be directly neurotoxic... - ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomasMichael B Streiff
Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
Cancer 100:1717-23. 2004..These findings may facilitate the development of a thrombosis risk score that will allow physicians to individualize VTE prophylaxis regimens... - Does decompressive surgery improve outcome in patients with metastatic epidural spinal-cord compression?David E Gerber
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Nat Clin Pract Neurol 2:10-1. 2006 - Management of venous thromboembolism in patients with primary and metastatic brain tumorsDavid E Gerber
Departments of Oncology, Medicine, and Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
J Clin Oncol 24:1310-8. 2006..When intracranial hemorrhage does occur, it is often due to overanticoagulation, requiring prompt anticoagulation reversal and neurosurgical consultation... - Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiformeTom Mikkelsen
Department of Neurology, Henry Ford Health System, Detroit, Michigan 48202, USA
Invest New Drugs 25:259-63. 2007..This study examined the efficacy, safety and pharmacokinetics of oral CAI in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM) in an open-label, single arm non-randomized phase 2 trial... - Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastomaSteven Brem
Department of Interdisciplinary Oncology and Neurosurgery, University of South Florida College of Medicine and Neuro Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL 33620, USA
Neuro Oncol 7:246-53. 2005..Although serum copper was effectively reduced by diet and penicillamine, this antiangiogenesis strategy did not improve survival in patients with glioblastoma multiforme... - Central nervous system cancers: Clinical Practice Guidelines in OncologySteven S Brem
J Natl Compr Canc Netw 3:644-90. 2005 - Adult cancer painRobert Swarm
National Comprehensive Cancer Network
J Natl Compr Canc Netw 5:726-51. 2007 - Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant gliomaSurasak Phuphanich
Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Neuro Oncol 10:617-23. 2008..Further study of atrasentan with radiation therapy and temozolomide in newly diagnosed GBM is warranted to evaluate the efficacy of this novel agent... - Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphomaBeela S Mathew
Regional Cancer Center, Trivandrum, India
Cancer Treat Rev 29:105-19. 2003..It also provides recommendations for Pneumocystis prophylaxis for this patient population... - Methylated tumor-specific DNA as a plasma biomarker in patients with gliomaKyle D Weaver
Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA
Cancer Invest 24:35-40. 2006..Patients with systemic malignancies have substantial quantities of tumor-specific DNA in their plasma which may serve as a potential biomarker for tumor burden. This approach has not been studied in gliomas... - Initial response to glucocorticoidsBeela S Mathew
Department of Radiation Oncology, Regional Cancer Center, Trivandrum, India
Cancer 106:383-7. 2006..14; 95% CI, 0.04-0.46) to glucocorticoids given before radiation or chemotherapy. CONCLUSION: This analysis suggests that initial response to treatment with glucocorticoids may be an important prognostic factor in patients with PCNSL... - Penetration of intra-arterially administered vincristine in experimental brain tumorFrances M Boyle
Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital, Sydney, NSW 2065, Australia
Neuro Oncol 6:300-5. 2004..The lack of penetration of vincristine into brain tumor and the paucity of single-agent activity studies suggest that vincristine should not be used in the treatment of primary brain tumors... - Central nervous system cancersSteven S Brem
H Lee Moffitt Cancer Center and Research Institute
J Natl Compr Canc Netw 6:456-504. 2008
Research Grants
- NABTT-Consortium Therapeutic Studies of CNS MalignanciesStuart Grossman; Fiscal Year: 2007..abstract_text> ..
- RESEARCH TRAINING IN NEURO-ONCOLOGYStuart Grossman; Fiscal Year: 2007..This program is designed to provide well-rounded research training to trainees and to develop them as the next generation of investigators in neuro-oncology. ..